Navidea Announces Lymphoseek® Presentations at Upcoming Medical Conferences
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that Lymphoseek® (technetium Tc 99m tilmanocept) injection data are scheduled for presentations at the following conferences: American Society of Breast Surgeons 16th Annual Meeting in Orlando, FL, and 2015 American Head & Neck Society Annual Meeting & Translational Research Meeting, held during the Combined Otolaryngology Spring Meetings (COSM) in Boston, MA. Details of the presentations are listed below.
|
2015 American Head & Neck Society Annual Meeting & Translational Research Meeting, held during the Combined Otolaryngology Spring Meetings (COSM) |
||||
|
April 21 - 23, 2015 Boston, MA |
||||
|
Session Type: |
Oral | |||
|
Date: |
April 22, 2015 | |||
|
Title: |
Pivotal Phase 3 Trial Results of 99mTc-Tilmanocept in Sentinel Lymph Node Detection in Oral Cancer Patients: Comparison of “Same Day” vs “Next Day” imaging and diagnostic efficacy in floor of mouth disease |
|||
|
Authors: |
Stephen Y. Lai1*, Amit Agrawal2, Frank Civantos3 |
|||
|
1M.D. Anderson Cancer Center, Houston, TX; 2The Ohio State University Wexner Medical Center, Columbus, OH; 3University of Miami Hospital, Miami, FL |
||||
|
*Presenter |
||||
| American Society of Breast Surgeons 16th Annual Meeting | ||||
|
April 29 – May 3, 2015 Orlando, FL |
||||
|
Session Type: |
Oral | |||
|
Date: |
May 2, 2015 | |||
|
Title: |
Sentinel node mapping with 99mTc-tilmanocept: clinical trial results and follow-up data show consistent performance across studies and tumor types |
|||
|
Authors: |
Anne Wallace1, Jennifer Baker2* |
|||
|
1Plastic Surgery, University of California - San Diego, San Diego, CA; 2Department of Surgery, University of California - San Diego, San Diego, CA |
||||
|
*Presenter |
||||
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™, NAV4694, and NAV5001, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals
Investors
Tom
Baker, 617-532-0624
tbaker@navidea.com
or
Media
Sharon
Correia, 978-655-2686
Associate Director, Corporate Communications
Source: Navidea Biopharmaceuticals, Inc.
Released April 15, 2015